{"commentary":{"count":26,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":17,"podcast":6,"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04712097\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"Celestimo","nct_id":"NCT04712097","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=celestimo-nct04712097. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"Celestimo","arms":[{"description":"Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)","label":"M + Len (Arm A)","type":"EXPERIMENTAL"},{"description":"Participants will receive weekly rituximab in Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11. Participants will also receive lenalidomide in Cycles 1-12. (Cycle length = 28 days for Cycles 1-12)","label":"R + Len (Arm B)","type":"EXPERIMENTAL"},{"description":"Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)","label":"M + Len (US Extension Arm C)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-12-31","type":"ESTIMATED"},"conditions":["Relapsed or Refractory Follicular Lymphoma"],"enrollment":{"count":478,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Mosunetuzumab","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Rituximab","type":"DRUG"},{"name":"Tociluzumab","type":"DRUG"}],"last_update":"2026-10-08","lead_sponsor":"Hoffmann-La Roche","official_title":"Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Non-Randomized Single Arm US Extension of Mosunetuzumab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-06-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) according to 2014 Lugano Response Criteria","timeFrame":"From randomization to the first occurrence of disease progression as determined by an independent review committee (IRC) or death from any cause (up to approximately 8.5 years)"}],"references":[],"start_date":{"date":"2021-10-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma","url":"https://clinicaltrials.gov/study/NCT04712097"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/celestimo-nct04712097"}